Ascendis Pharma submits sBLA for growth hormone deficiency therapy
Pharmaceutical Technology
OCTOBER 1, 2024
Ascendis Pharma has submitted a supplemental biologics licence application (sBLA) to the US Food and Drug Administration (FDA) for TransCon hGH to treat adults with growth hormone deficiency (GHD).
Let's personalize your content